IPO Trending
AHCLEQ / NSE, BSEListed
Anlon Healthcare

Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company specializing in the production of pharma intermediates and active pharmaceutical ingredients (APIs). It manufactures high-purity pharmaceutical intermediates used in API production and APIs that are utilized in medicines, nutraceuticals, personal care, and animal health products. The company’s offerings are produced in compliance with Indian and international pharmacopeia standards such as IP, BP, EP, JP, and USP. Along with manufacturing APIs and intermediates to global standards, Anlon Healthcare also provides custom manufacturing for complex chemicals, focusing on exceeding purity standards and minimizing impurities to meet customer-specific requirements. The company has obtained Drug Master File (DMF) approval from regulatory authorities including ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. It has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals. Its portfolio comprises 65 commercialized products, 28 at the pilot stage, and 49 undergoing laboratory testing. To ensure consistent product quality, the company follows rigorous testing and process improvements, supported by four laboratories and a 34-member technical team, which includes 24 science graduates. The company’s product range includes pharmaceutical intermediates such as Cyanoethylbenzoic acid, Ketonitrile, and Methyldesloratadine, which serve as key starting materials or advanced intermediates for API manufacturing. Its APIs are essential components in pharmaceutical products, delivering therapeutic effects and being used in various formulations like tablets, capsules, ointments, and syrups, as well as in nutraceuticals, personal care, and veterinary products. As of January 31, 2025, Anlon Healthcare employed 105 people (excluding trainees) along with 8 contract workers.

₹86 - ₹917.13x sub
Listed Price₹92.00
Listing Gain+1.10%

Subscription Status

7.13xTotal Demand
Updated 20 Oct 2026, 01:30 AM
QIB1.07x
Fully Subscribed (Safe)Offered: 99,75,000 sh
Nib10.61x
Hot Bidding (High Profits)Offered: 19,95,000 sh
Hnis(10l +)7.56x
Popular / Warm DemandOffered: 13,30,000 sh
Hnis (2-10l)16.69x
Hot Bidding (High Profits)Offered: 6,65,000 sh
Retail47.30x
🔥 Blockbuster Sizzling Demand!Offered: 13,30,000 sh
CategoryOfferedAppliedTimes
QIB99,75,0001,06,89,0281.07x
Nib19,95,0002,11,61,41210.61x
Hnis(10l +)13,30,0001,00,59,9247.56x
Hnis (2-10l)6,65,0001,11,01,48816.69x
Retail13,30,0006,29,12,36847.3x

Segment Subscription Demand

Segment / CategoryDemand (Shares)Offered (Shares)Times Sub.
QIB97.2790.771.07x
Retail572.512.147.31x
Hnis 2+101.026.0516.70x
Hnis 10+91.5512.17.57x

Application-wise Breakup

CategoryReservedAppliedTimes Sub.
Retail8,1103,34,69741.27x
Hnis(10l +)5798781.52x
Hnis (2-10l)2904,62815.96x
Bidding status cross-verified with live IPO subscription numbers ↗BSE & NSE Bidding Portal Feed

About Anlon Healthcare IPO Subscription Demand

Live subscription status and bidding analysis for Anlon Healthcare (AHCL) IPO. The issue is subscribed 7.13x overall across Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII/HNI), and Retail Individual Investors (RII). Check real-time grey market demand on our GMP Tracker or review full issue details, lot size, and price band on the IPO Details Page.

Frequently Asked Questions